|
| 37993699 | Digoxin Pharmacokinetics in Patients with Obesity Before and After a Gastric Bypass or a Strict Diet Compared with Normal Weight Individuals. | Clin Pharmacokinet | 2024 |
| 36988826 | Neither Gastric Bypass Surgery Nor Diet-Induced Weight-Loss Affect OATP1B1 Activity as Measured by Rosuvastatin Oral Clearance. | Clin Pharmacokinet | 2023 |
| 37711184 | Proteome deconvolution of liver biopsies reveals hepatic cell composition as an important marker of fibrosis. | Comput Struct Biotechnol J | 2023 |
| 34435745 | Short- and long-term effects of body weight loss following calorie restriction and gastric bypass on CYP3A-activity - a non-randomized three-armed controlled trial. | Clin Transl Sci | 2022 |
| 35648149 | Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range. | Eur J Clin Pharmacol | 2022 |
| 35404513 | Short- and long-term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity. | Br J Clin Pharmacol | 2022 |
| 36037309 | Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity. | Clin Transl Sci | 2022 |
| 36126230 | A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II. | CPT Pharmacometrics Syst Pharmacol | 2022 |
| 35158408 | Drug Disposition Protein Quantification in Matched Human Jejunum and Liver From Donors With Obesity. | Clin Pharmacol Ther | 2022 |
| 35338410 | Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy. | AAPS J | 2022 |
| 32970864 | Proteomics-Informed Prediction of Rosuvastatin Plasma Profiles in Patients With a Wide Range of Body Weight. | Clin Pharmacol Ther | 2021 |
| 33626278 | Glucagon Like Peptide 1 Receptor Agonists for Targeted Delivery of Antisense Oligonucleotides to Pancreatic Beta Cell. | J Am Chem Soc | 2021 |
| 33848634 | Comparisons of basic target-mediated drug disposition (TMDD) and ligand facilitated target removal (LFTR). | Eur J Pharm Sci | 2021 |
| 33667667 | Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs. | Eur J Pharm Sci | 2021 |
| 34252098 | Enantiospecific antitrypanosomal in vitro activity of eflornithine. | PLoS Negl Trop Dis | 2021 |
| 33980578 | An oral antisense oligonucleotide for PCSK9 inhibition. | Sci Transl Med | 2021 |
| 33091408 | Correlation of Body Weight and Composition With Hepatic Activities of Cytochrome P450 Enzymes. | J Pharm Sci | 2021 |
| 32275768 | Does In Vitro Potency Predict Clinically Efficacious Concentrations? | Clin Pharmacol Ther | 2020 |
| 32984708 | Chiral Chromatographic Isolation on Milligram Scale of the Human African Trypanosomiasis Treatment d- and l-Eflornithine. | ACS Omega | 2020 |
| 32359836 | Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades. | Trends Pharmacol Sci | 2020 |
| 30529076 | Corrigendum to 'Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development' Drug Discovery Today 23 (2018) 1733-1745. | Drug Discov Today | 2019 |
| 31410806 | ADME: Assessing Pharmacokinetic-Pharmacodynamic Parameters of Oligonucleotides. | Methods Mol Biol | 2019 |
| 31292220 | Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia. | J Lipid Res | 2019 |
| 30813831 | The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone. | J Renin Angiotensin Aldosterone Syst | 2019 |
| 30596500 | Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection. | J Med Chem | 2019 |
| 29468715 | Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator. | Br J Clin Pharmacol | 2018 |
| 29852223 | Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development. | Drug Discov Today | 2018 |
| 30345352 | Targeted delivery of antisense oligonucleotides to pancreatic β-cells. | Sci Adv | 2018 |
| 30564457 | Mathematical model of hemodynamic mechanisms and consequences of glomerular hypertension in diabetic mice. | NPJ Syst Biol Appl | 2018 |
| 30328765 | Inferring Half-Lives at the Effect Site of Oligonucleotide Drugs. | Nucleic Acid Ther | 2018 |
| 29474466 | Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. | PLoS One | 2018 |
| 28754465 | Evaluation of pharmacokinetic and pharmacodynamic profiles of liposomes for the cell type-specific delivery of small molecule drugs. | Nanomedicine | 2017 |
| 27377054 | Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. | Diabetes Obes Metab | 2016 |
| 27318707 | Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs. | Parkinsonism Relat Disord | 2016 |
| 25512417 | Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness. | Antimicrob Agents Chemother | 2015 |
| 23307171 | Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat. | J Pharmacokinet Pharmacodyn | 2013 |
| 24158456 | A modeling approach for compounds affecting body composition. | J Pharmacokinet Pharmacodyn | 2013 |
| 23726890 | Model-based drug discovery: implementation and impact. | Drug Discov Today | 2013 |
| 22690905 | Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. | Acta Neurol Scand | 2012 |
| 21046209 | Feedback modeling of non-esterified fatty acids in rats after nicotinic acid infusions. | J Pharmacokinet Pharmacodyn | 2011 |
| 20020417 | Determination of eflornithine enantiomers in plasma by precolumn derivatization with o-phthalaldehyde-N-acetyl-L-cysteine and liquid chromatography with UV detection. | Biomed Chromatogr | 2010 |
| 17724666 | Prediction of drug tissue to plasma concentration ratios using a measured volume of distribution in combination with lipophilicity. | J Pharm Sci | 2008 |
| 18519728 | Enantioselective and nonlinear intestinal absorption of eflornithine in the rat. | Antimicrob Agents Chemother | 2008 |
| 16972163 | Feasibility and validity of a computer administered version of SEIQoL-DW. | Qual Life Res | 2006 |
| 15668416 | Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. | Neurology | 2005 |
| 16275852 | Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. | Neurology | 2005 |